Opportunity BasketIBM Patient Registry & Natural History Cohort Service
A specialized patient recruitment and longitudinal data collection service that enrolls IBM patients into a managed registry, capturing standardized clinical assessments (muscle strength, functional decline, biomarkers) at regular intervals. The service handles all IRB compliance, patient consent, data standardization, and secure storage—then licenses de-identified cohort data to pharma companies running trials or seeking real-world evidence on disease progression patterns.
56 weeks • 70% confidence
Value Proposition
Pharma companies waste millions on failed IBM trials because they don't understand true disease heterogeneity and progression rates in real populations. This service provides pre-validated, longitudinally-tracked patient cohorts with 24+ months of standardized data, eliminating the guesswork in trial design and allowing companies to identify responder subpopulations before investing in Phase 3. Beats existing registries (which are passive, incomplete, and fragmented) by actively managing patient engagement and enforcing data quality.
Target Audience
Pharmaceutical companies running IBM clinical trials; biotech firms seeking natural history data to inform trial design; CROs designing IBM studies
Key Features
- Active patient recruitment through neuromuscular clinics and patient advocacy groups (IBM Research Trust, Myositis Association)
- Standardized quarterly assessments: manual muscle testing (MMT), IBM Functional Rating Scale (IBMFRS), timed walk tests, biomarker collection (CK, myositis antibodies)
- Real-time dashboard showing cohort demographics, progression rates, and subgroup stratification (seropositive vs. seronegative, age of onset, comorbidities)
- And more, with full implementation detail...
Tech Stack
Unlock the full solution
You're seeing a preview. Unlock the complete value proposition, every feature, the full tech stack, the monetization model, and the week-by-week build roadmap, plus a downloadable PDF.
Sign up free to continue3 free solution credits on signup
The build plan is behind the wall
Subscribers get the full monetization model, pricing strategy, and the complete week-by-week roadmap to build this.
Sign up freeOriginal Problem
Inclusion Body Myositis patients have no approved treatment options despite progressive muscle deteriorationPatients with inclusion body myositis (IBM) suffer from worsening muscle weakness with zero FDA-approved drugs available, forcing them to endure progressive disability without therapeutic options. Current clinical trials fail to show efficacy across patient populations, leaving physicians and patients desperate for any viable treatment. The lack of approved therapeutics means patients watch their condition deteriorate while pharmaceutical companies struggle to develop effective interventions.
Score: 49.6% • 1 payment signal